- Home
- ARQT vs PGNY Comparison
ARQT vs PGNY Comparison
Compare ARQT & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- PGNY
- Stock Information
- Founded
- ARQT 2016
- PGNY 2008
- Country
- ARQT United States
- PGNY United States
- Employees
- ARQT N/A
- PGNY N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- PGNY Misc Health and Biotechnology Services
- Sector
- ARQT Health Care
- PGNY Health Care
- Exchange
- ARQT Nasdaq
- PGNY Nasdaq
- Market Cap
- ARQT 2.0B
- PGNY 1.9B
- IPO Year
- ARQT 2020
- PGNY 2019
- Fundamental
- Price
- ARQT $13.80
- PGNY $21.11
- Analyst Decision
- ARQT Strong Buy
- PGNY Buy
- Analyst Count
- ARQT 6
- PGNY 9
- Target Price
- ARQT $18.80
- PGNY $22.71
- AVG Volume (30 Days)
- ARQT 2.6M
- PGNY 1.6M
- Earning Date
- ARQT 05-13-2025
- PGNY 05-08-2025
- Dividend Yield
- ARQT N/A
- PGNY N/A
- EPS Growth
- ARQT N/A
- PGNY N/A
- EPS
- ARQT N/A
- PGNY 0.57
- Revenue
- ARQT $196,542,000.00
- PGNY $1,167,221,000.00
- Revenue This Year
- ARQT $60.21
- PGNY $5.81
- Revenue Next Year
- ARQT $40.21
- PGNY $11.34
- P/E Ratio
- ARQT N/A
- PGNY $38.26
- Revenue Growth
- ARQT 229.74
- PGNY 7.22
- 52 Week Low
- ARQT $6.99
- PGNY $13.39
- 52 Week High
- ARQT $17.75
- PGNY $33.84
- Technical
- Relative Strength Index (RSI)
- ARQT 46.44
- PGNY 41.47
- Support Level
- ARQT $12.51
- PGNY $21.49
- Resistance Level
- ARQT $13.67
- PGNY $22.81
- Average True Range (ATR)
- ARQT 1.43
- PGNY 0.97
- MACD
- ARQT -0.27
- PGNY -0.14
- Stochastic Oscillator
- ARQT 34.83
- PGNY 11.84
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About PGNY Progyny Inc.
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.